additional survivors compared to immediate administration at 22 weeks. Overall, delaying administration of antenatal steroids by three weeks led to higher QALYS when compared to immediate treatment. However, there would be 10 more neonates with respiratory distress syndromes, 20 more intraventricular hemorrhage, and 11 more children with neurodevelopmental delay. With sensitivity analysis, we found that as long as the probability of survival at 25 weeks gestation is less than 81%, then delaying administration by three weeks remains the optimal strategy. CONCLUSION: Our results support that the optimal time for administration of antenatal corticosteroids in women with PPROM at 22 weeks is three weeks after presentation at 25 weeks gestation to reduce mortality and minimize morbidity. These findings can be used to counsel women presenting in the periviable period.
537 Timing of antenatal corticosteroids for severe preeclampsia at 22 weeks: a decision analysis Clarice G. Zhou, James Sargent, Aaron B. Caughey
Oregon Health & Science University, Portland, OR OBJECTIVE: Preterm delivery secondary to preeclampsia have severe neonatal complications, although incidences can be reduced with antenatal corticosteroid treatment. Despite their benefits, there is evidence that the effects of steroids decrease 7 days after treatment, thus the timing of administration following presentation impacts neonatal outcomes. The objective of this study was to use a decision analysis to determine the optimal time for steroid administration for women with severe preeclampsia at 22 weeks. STUDY DESIGN: A decision-analytic model was constructed using TreeAge software to compare neonatal mortality and morbidity following steroid treatment in a theoretical cohort of 1,000 women who present with severe preeclampsia at 22 weeks. The model compared administering steroids immediately at presentation (22 weeks), at 1 week (23 weeks), and at 2 weeks (24 weeks) following presentation. The outcomes of neonatal death, respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), and neurodevelopmental delay were assessed along with quality-adjusted life years (QALYs). All probabilities, utilities, and costs were derived from literature. Costs are expressed in 2018 US dollars with a willingness to pay threshold (WTP) set at $100,000/QALY. Deterministic and probabilistic sensitivity analyses were performed to interrogate model assumptions. RESULTS: In our theoretical cohort of 1,000 women who present with preeclampsia at 22 weeks, administering steroids one week after presentation resulted in 12 additional survivors compared to immediate treatment at 22 weeks and 163 more survivors compared to waiting until week 24. Giving steroids at 23 weeks gestation led to 16 fewer neonates with RDS, 32 fewer neonates with IVH, and 12 fewer children with neurodevelopmental delay. Overall, delaying administration of antenatal steroids by one week led to higher QALYS when compared to immediate treatment. With sensitivity analysis, we found that as long as the probability of survival at 23 weeks gestation is less than 55%, then delaying administration remains the optimal strategy.
CONCLUSION:
Our results support that the optimal time for administration of antenatal corticosteroids in women with severe preeclampsia at 22 weeks is one week after presentation at 23 weeks gestation to reduce morbidity and mortality. These findings can be used to counsel women presenting in the periviable period. OBJECTIVE: This study analyzes differences in maternal and neonatal outcomes from elective induction of labor (eIOL) at 39 weeks versus one additional week of expectant management in nulliparous women at community hospitals. STUDY DESIGN: We conducted a retrospective cohort study of singleton, vertex, nonanomalous deliveries in community hospitals in California between 2007 and 2011 using linked hospital discharge and vital statistics data (n¼252,107). We compared outcomes from eIOL, defined by the Joint Commission, at 39 weeks against one additional week of expectant management and delivery at 40 weeks. The maternal outcomes of interest were cesarean delivery, operative vaginal delivery, maternal blood transfusion, perineal tear, chorioamnionitis, and endomyometritis. Neonatal outcomes of interest were intrauterine fetal death, 5 minute Apgar less than 7, NICU admission, respiratory distress syndrome (RDS), hypoglycemia, hypoxic ischemic encephalopathy (HIE) and jaundice. Results were compared using chi square analysis and examined using multivariate logistic regression controlling for maternal age, comorbidities, ethnicity, education level, initiation of prenatal care in the first trimester, and insurance status. A p-value of less than 0.05 was used to indicate statistical significance. RESULTS: In our cohort of 252,107 deliveries, there were significant differences in the incidence of cesarean delivery, operative vaginal delivery, maternal transfusion, perineal tear, chorioamnionitis, endomyometritis in women who were electively induced at 39 weeks compared to those who received expectant management and delivered at 40 weeks. Rates of adverse neonatal outcomes of intrauterine fetal death and hypoglycemia were also significantly decreased when women were electively induced at 39 weeks. However, RDS, HIE and jaundice were not significantly different between the two groups. Logistic regression analysis indicated expectant management until 40 weeks significantly increased cesarean deliveries (OR 1.37, 95% CI 1.32-1.42) and operative vaginal deliveries (OR 1.0, 95% CI 1.02-1.15). CONCLUSION: The maternal and neonatal outcomes following birth are associated with the timing and management prior to delivery. These findings can be used to counsel women regarding the risks of maternal and neonatal complications from elective induction of labor and one additional week of expectant management.
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